Payment overview · 2025
General Payments
$370.50
16 reported records · 6 companies
Healthcare provider profile · identity verified
Mark Standridge Bradshaw, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WYNNE, AR · NPI 1346355518
Verified facts
What the public records show
CMS Open Payments records show Mark Standridge Bradshaw, M.D. received $370.50 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 63.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $234.78 | 63.4% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.30 | 12.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.06 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.42 | 7.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.12 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.82 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $370.50 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $205.00 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.30 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.55 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 188 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
188 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 616 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 454 | 113 |
| Omeprazole | Omeprazole | 440 | 97 |
| Gabapentin | Gabapentin | 360 | 82 |
| Tramadol Hcl | Tramadol Hcl | 339 | 75 |
| Furosemide | Furosemide | 329 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 311 | 83 |
| Potassium Chloride | Potassium Chloride | 298 | 76 |
| Losartan Potassium | Losartan Potassium | 263 | 61 |
| Lorazepam | Lorazepam | 259 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 62 |
| Metformin Hcl Er | Metformin Hcl | 240 | 66 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 237 | 52 |
| Glimepiride | Glimepiride | 205 | 47 |
| Lisinopril | Lisinopril | 199 | 51 |
| Meloxicam | Meloxicam | 190 | 57 |
| Eliquis | Apixaban | 188 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 66 |
| Sertraline Hcl | Sertraline Hcl | 170 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 163 | 36 |
| Ondansetron Odt | Ondansetron | 163 | 59 |
| Celecoxib | Celecoxib | 161 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 38 |
| Simvastatin | Simvastatin | 153 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 52 |
| Carvedilol | Carvedilol | 148 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 28 |
| Methylprednisolone | Methylprednisolone | 142 | 111 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 28 |
| Allopurinol | Allopurinol | 132 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 31 |
| Pregabalin | Pregabalin | 130 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 33 |
| Metformin Hcl | Metformin Hcl | 123 | 32 |
| Clonazepam | Clonazepam | 115 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 109 | 38 |
| Buspirone Hcl | Buspirone Hcl | 104 | 24 |
| Montelukast Sodium | Montelukast Sodium | 101 | 20 |
| Enalapril Maleate | Enalapril Maleate | 100 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 25 |
| Diazepam | Diazepam | 93 | 13 |
| Finasteride | Finasteride | 89 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 21 |
| Trazodone Hcl | Trazodone Hcl | 87 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 19 |
| Alprazolam | Alprazolam | 82 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 22 |
| Cefdinir | Cefdinir | 77 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 16 |
| Methocarbamol | Methocarbamol | 75 | 29 |
| Naproxen | Naproxen | 74 | 21 |
| Azithromycin | Azithromycin | 73 | 65 |
| Famotidine | Famotidine | 72 | 18 |
| Atenolol | Atenolol | 66 | 18 |
| Cephalexin | Cephalexin | 64 | 52 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 62 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 16 |
| Ezetimibe | Ezetimibe | 60 | 21 |
| Clonidine Hcl | Clonidine Hcl | 58 | 15 |
| Prednisone | Prednisone | 57 | 48 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 14 |
| Ozempic | Semaglutide | 56 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 29 |
| Valsartan | Valsartan | 55 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 41 |
| Synthroid | Levothyroxine Sodium | 54 | 12 |
| Glipizide | Glipizide | 53 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 21 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Fluconazole | Fluconazole | 49 | 34 |
| Mirtazapine | Mirtazapine | 48 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 11 |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 31 |
| Nystatin | Nystatin | 44 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 34 |
| Nitroglycerin | Nitroglycerin | 41 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 41 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 13 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 15 |
| Baclofen | Baclofen | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 11 |
| Cefuroxime | Cefuroxime Axetil | 24 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 16 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Victoza 3-Pak | Liraglutide | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $370.50 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error